Top Markets
#1 Useless Coin Useless Coin +38.89%
#2 Merlin's Seal BTC Merlin's Seal BTC +37.87%
#3 0G 0G +35.68%
#4 StonkBroker StonkBroker +33.02%
#5 SAFEcoin SAFEcoin +30.29%
#6 Zora Zora +20.93%
#7 Arbitrum Arbitrum +20.92%
#8 Full Moon Full Moon +18.06%
#9 Dogs Dogs +17.66%
#10 Notcoin Notcoin +17.14%
Coin of the day
Useless Coin Useless Coin
설정
언어
한국어
통화
USD
테마
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
주식 순위 #13828
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
주가
$4.36
시가총액
$457.32M
변동 (1일)
0.69%
변동 (1년)
289.29%
국가
US
거래 Relmada Therapeutics, Inc. (RLMD)

카테고리

Healthcare
Relmada Therapeutics, Inc. (RLMD)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Relmada Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Relmada Therapeutics, Inc.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH